AI assistant
Sending…
BridgeBio Pharma, Inc. — Director's Dealing 2025
Nov 8, 2025
30604_dirs_2025-11-07_21058bdb-81d0-4a64-9d4a-76da0b057558.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: BridgeBio Pharma, Inc. (BBIO)
CIK: 0001743881
Period of Report: 2025-11-06
Reporting Person: DANIELS RONALD J (Director)
Non-Derivative Transactions
| Date | Security | Code | Shares | Price | A/D | Holdings After | Ownership |
|---|---|---|---|---|---|---|---|
| 2025-11-06 | Common Stock | M | 61031 | $34.65 | Acquired | 78022 | Direct |
| 2025-11-06 | Common Stock | S | 61031 | $63.7217 | Disposed | 16991 | Direct |
Derivative Transactions
| Date | Security | Exercise Price | Code | Shares | A/D | Expiration | Underlying | Ownership |
|---|---|---|---|---|---|---|---|---|
| 2025-11-06 | Stock Option (Right to Buy) | $34.65 | M | 61031 | Disposed | 2030-02-11 | Common Stock (61031) | Direct |
Footnotes
F1: Represents the weighted average sale price of the shares sold from $63.70 to $63.88 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price for all transactions within the range set forth in this footnote.
F2: The shares subject to this option vested and became exercisable in three annual installments from February 12, 2020 to February 12, 2023.
More from BridgeBio Pharma, Inc.
Capital/Financing Update
2026
Jul 2
Board/Management Information
2026
Jun 26
Call Transcript
2026
Jun 22
Call Transcript
2026
Jun 4
Regulatory Filings
2026
May 27
Regulatory Filings
2026
May 13
Call Transcript
2026
May 12
Capital/Financing Update
2026
May 8
Interim / Quarterly Report
2026
May 7
Call Transcript
2026
May 7